Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by quest13on Oct 05, 2020 4:19pm
173 Views
Post# 31668458

RE:RE:RE:Off topic but of interest. ZENITH

RE:RE:RE:Off topic but of interest. ZENITH i AM POSTING WITH CAPLOCK ON TO MAKE IT EASIER FOR YOU TO READ WITH YOUR EYESIGHT PROBLEMS Jkj.

THE VALUE PUT ON OUR SHARES BY ANY OF THE BROKERS WILL ONLY BECOME REALISTIC WHEN THE COMPANY LISTS THE SHARES ON A  STOCK EXCHANGE,  iT REMAINS A PUBLIC COMPANY (BUT NOT LISTED ON A STOCK EXCHANGE) (MEANING THERE ARE MORE THAN THE MAXIMUM NUMBER OF SHAREHOLDERS ALLOWED FOR A PRIVATE COMPANY) THE COMPANY REPORTS ALL REQUIRED RESULTS ON SEDAR.

i BELIEVE THAT A BROKER WHO DOES NOT GET SIDETRACKED BY THE NEW COMPANY WHICH IS LISTED AND WORTH ABOUT 20 CENTS. THE PART OF THE NAME BEING CORP FOR US AND CORPORATION FOR THEM IS WHAT CAUSES ALL THE CONFUSION.

I DEAL WITH CIBC AND THEY SHOW AND HAVE SHOWN FOR A WHILE A VALUE OF $1.331 WHICH I BELIEVE IS CALCULATED BY WHAT I CALL ACCOUNTING "JIGGERY POKERY" OR CALCULATION BASED ON BOOK VALUES SHOWN ON THE STATEMENT ON SEDAR.

I BELIEVE IT WILL ONLY CHANGE WHEN A DEAL IS DONE FOR SALE OF ZCC OR MORE LIKELY ZENITH EPIGENETICS WHICH IS THE SUBSIDIARY OF ZCC. Zenith Capital Corp.


Bullboard Posts